Also known as: WHO, World Health Organisation
Ebola Virus Disease remains a public health concern due to its high fatality rate. A new outbreak has been confirmed in Congo’s Ituri province, while early treatment and approved monoclonal antibodies can enhance survival.
ImmunityBio said the Saudi FDA encouraged submission of a regulatory package for recombinant BCG and opened talks on expanding ANKTIVA with checkpoint inhibitors to additional tumor types. The company expects to file the rBCG package within weeks.
Three advances in TB diagnostics: a portable $300 device delivering results in 30 minutes, a Quick DNA kit detecting drug resistance in 5 minutes, and an ultrasensitive test finding TB DNA in 12-16% of hospitalized US patients.
A retrospective study found that myocarditis within the first month after immune checkpoint inhibitor initiation was linked to higher mortality risk. The analysis identified 4,635 cases in VigiBase.
GLP-1 drugs used for type 2 diabetes and obesity are seeing rising demand for weight loss as safety concerns also draw attention. A 2025 WHO guideline said long-term safety data remains limited.
Laguna won FDA Breakthrough Device Designation for a blood-based schizophrenia test, while Neurocrine dosed the first patient in a Phase 2 trial of NBI-1117570.
WHO has prequalified Coartem Baby, the first malaria treatment developed for newborns and young infants weighing 2 to 5 kilograms. The decision opens access through public procurement and donor-funded programs.
WHO in January 2024 launched its first list of priority childhood cancer drug formulations, naming six medicines that still lack optimal child-friendly versions. The agency says about 400,000 children and adolescents develop cancer each year and is working to expand access to safe, effective paediatric formulations.
The UK has begun a 4,000-volunteer H5N1 bird flu vaccine trial using mRNA technology. The study will assess safety and immune response, with CEPI providing £40m in funding.
The global cancer monoclonal antibodies market was valued at USD 66.7 billion in 2025 and is expected to reach USD 135.2 billion by 2033. Growth is being driven by targeted therapies, bispecific antibodies, ADCs and checkpoint inhibitors.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07432126 |
Community Health Workers Led Integrated Management of Hypertension and Diabetes in Nepal |
RECRUITING | NA |
| NCT07236268 |
Prevalence of HIV and Sexually Transmitted Infections in Migrant Communities in Slovakia |
COMPLETED | |
| NCT07145736 |
Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases |
RECRUITING | PHASE4 |
| NCT07129837 |
Serum Anti-PCOLCE as Novel Diagnostic Biomarker in Rheumatoid Arthritis With Emphasis on Seronegative Patients. |
NOT_YET_RECRUITING | |
| NCT07116447 |
Impact of Alcohol Health Messages in a Real-world Online Retail Setting |
COMPLETED | NA |
| NCT07071792 |
Prevalence of Helmet Associated Neck Pain Among TCS Riders |
COMPLETED | |
| NCT07012876 |
Effectiveness of a Guided Mental Health Chatbot for Youth Living in Lithuania |
ACTIVE_NOT_RECRUITING | NA |
| NCT07008950 |
Self-efficacy and Knowledge (SEEK) Trial to Improve Sexual Reproductive Health and Well-being for Syrian Refugee Women and Girls in Lebanon |
RECRUITING | NA |
| NCT06989398 |
Implementation of the ASCEND Training for Supervisors in Dutch Small and Medium-sized Enterprises (SMEs) |
RECRUITING | NA |
| NCT06979089 |
Implementation of DWM in Dutch SMEs |
RECRUITING | NA |
